ID: hyp-SDA-2026-04-09-gap-debate-20260409-2
Hypothesis
Glycan-Based Drug Delivery to Tau Vesicles
Neuroprotective compounds conjugated to specific glycan structures would selectively accumulate in tau-containing vesicles, providing targeted delivery of therapeutic agents.
EvidencePending (0%)📖 2 cit🗣 1 debates✓ 2 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Neuroprotective compounds conjugated to specific glycan structures would selectively accumulate in tau-containing vesicles, providing targeted delivery of therapeutic agents. This Trojan horse approach exploits the unique glycan signatures as delivery addresses.
🧬 Mechanism
🔗 Mechanism from KG for ST6GAL1
Auto-built from this analysis's top knowledge-graph edges.
graph TD
ST6GAL1["ST6GAL1"] -->|regulates| sialylation["sialylation"]
ST6GAL1_1["ST6GAL1"] -->|catalyzes| sialylation_2["sialylation"]
ST6GAL1_3["ST6GAL1"] -->|associated with| tau_spreading["tau_spreading"]
style ST6GAL1 fill:#ce93d8,stroke:#333,color:#000
style sialylation fill:#ffd54f,stroke:#333,color:#000
style ST6GAL1_1 fill:#ce93d8,stroke:#333,color:#000
style sialylation_2 fill:#4fc3f7,stroke:#333,color:#000
style ST6GAL1_3 fill:#ce93d8,stroke:#333,color:#000
style tau_spreading fill:#4fc3f7,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix2 supports2 contradicts
Supports
Latent trait modeling of tau neuropathology in progressive supranuclear palsy.
Supports
Differences in CD75s- and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinomas and nontumoral liver tissues.
Contradicts
Disease-associated glycans on cell surface proteins.
Contradicts
Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — ST6GAL1
No curated PDB or AlphaFold mapping for ST6GAL1 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ST6GAL1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0535
Events (7d)
0
Price History
▲6.0%💾 Resource Usage
LLM Tokens
14,284
$0.0857
Total Cost
$0.0857
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF a neuroprotective compound is conjugated to ST6GAL1-preferred glycan structures (α-2,6-linked sialic acid) and applied to neurons from a tauopathy mouse model (PS19), THEN it will accumulate at ≥2- | Subcellular fractionation and immunofluorescence will show glycan-conjugated compound colocalization with tau-positive vesicles at 2-fold or greater enrichment | — no observation — | pending | 0.45 |
| IF ST6GAL1 is genetically silenced using CRISPR interference in SH-SY5Y cells with inducible tau overexpression, THEN the selectivity of glycan-conjugated drug accumulation in tau-positive vesicles wi | ST6GAL1 knockdown will reduce tau-vesicle selectivity index by ≥60%, with no change in overall cell viability, as quantified by high-content imaging | — no observation — | pending | 0.40 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF a neuroprotective compound is conjugated to ST6GAL1-preferred glycan structures (α-2,6-linked sialic acid) and applied to neurons from a tauopathy mouse model (PS19), THEN it will accumulate at ≥2-fold higher concentration in tau-positive vesicles compared to tau-negative vesicles within 4 hours
Predicted outcome: Subcellular fractionation and immunofluorescence will show glycan-conjugated compound colocalization with tau-positive vesicles at 2-fold or greater e
Falsification: Glycan-conjugated compound accumulates equally or less in tau-positive vesicles compared to tau-negative vesicles; or no significant difference from unconjugated compound
pendingconf 40%
IF ST6GAL1 is genetically silenced using CRISPR interference in SH-SY5Y cells with inducible tau overexpression, THEN the selectivity of glycan-conjugated drug accumulation in tau-positive vesicles will decrease by ≥60% compared to ST6GAL1-expressing controls within 72 hours of knockdown.
Predicted outcome: ST6GAL1 knockdown will reduce tau-vesicle selectivity index by ≥60%, with no change in overall cell viability, as quantified by high-content imaging
Falsification: ST6GAL1 knockdown does not reduce glycan-conjugate selectivity for tau vesicles (difference <30%) OR causes non-specific cytotoxicity confounding interpretation
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.